Business
Change of Registered Office
Change of Registered Office.
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n 31 March 2023\n \n \n \n \n \n \n \n \n Fusion Antibodies plc\n \n \n \n (\"Fusion\" or the \"Company\")\n \n \n \n \n \n \n Change of registered office\n \n \n \n \n \n \n \n \n Fusion Antibodies plc (AIM: FAB), a contract research organisation providing discovery, design, and optimisation services for therapeutic antibodies to the global healthcare market, announces that it has changed the address of its registered office with immediate effect to:\n \n \n \n \n \n Springbank Industrial Estate\n \n \n 1 Springbank Rd\n \n \n Dunmurry\n \n \n Belfast\n \n \n BT17 0QL\n \n \n \n \n \n \n Enquiries: \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fusion Antibodies plc\n \n \n \n \n \n www.fusionantibodies.com\n \n \n \n \n \n \n Adrian Kinkaid, Chief Executive Officer\n \n \n James Fair, Chief Financial Officer\n \n \n \n \n \n Via Walbrook PR\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Allenby Capital Limited\n \n \n \n \n \n Tel: +44 (0)20 3328 5656 \n \n \n \n \n \n \n James Reeve/Vivek Bhardwaj (Corporate Finance)\n \n \n Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Walbrook PR\n \n \n \n \n \n Tel: +44 (0)20 7933 8780 or [email protected]\n \n \n \n \n \n \n Anna Dunphy\n \n \n \n \n Mob: +44 (0)7876 741 001\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n About Fusion Antibodies plc\n \n \n \n \n \n \n Fusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the discovery and development of antibodies for both therapeutic drug and diagnostic applications.\n \n \n \n \n \n The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody design, generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenc...